News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Acelity CEO: SA bioetech firm's U.S. product launch part of bigger global plan
April 18, 2016

W. Scott Bailey, San Antonio Business Journal

Acelity's decision to introduce its TIELLE Foam Dressing Family of products in the U.S. will broaden the San Antonio-based company's advanced wound-therapeutics portfolio. It could also better position Acelity to become a more prominent international player in wound-care and regenerative medicine.

While Acelity expects to gain from the product launch in the U.S., the Alamo City could also come out of this a winner.

"It allows us to create, here in San Antonio, a global leader in wound therapeutics and regenerative healing," said Acelity CEO Joe Woody about the U.S. product roll-out. "The launch of our advanced foam dressing line not only gives clinicians access to a broader and complementary product portfolio, it also marks a significant milestone in our corporate transformation."

The dressings now being offered to clinicians in the U.S. can be used on a variety of wounds, including pressure ulcers, lower extremity ulcers, minor burns and donor sites. The TIELLE products can also be used on traumatic and post-surgical wounds. The product launch will benefit patients in America who will now have access to more wound-care treatments.

In 2013, Woody led what was then KCI's acquisition of Systagenix, formerly Johnson & Johnson’s advanced wound care division, which introduced TIELLE dressings in Europe in 1992. That moved followed KCI's purchase of LifeCell in 2008.

In 2014, all of the entities were rebranded as Acelity. Now, company officials are capitalizing on that series of transactions.

"Combining KCI, LifeCell and Systagenix as Acelity has enabled us to offer solutions beyond negative pressure wound therapy and build stronger relationships with doctors and nurses," Woody said. "Bringing the TIELLE Family of foam dressings to the U.S. is an example of that."

This new offering is an important step that advances Acelity's broader game plan, which includes more strategic acquisitions and geographic expansion. The end goal is to position Acelity as a one-stop shop for wound care.

Woody said there are more moves in the works that will further reinforce Acelity's global role in wound therapy.

"We will continue to focus on innovation and acquisitions in adjacent clinical areas to further expand our product portfolio going forward," Woody said.

W. Scott Bailey covers health care, tourism, sports business, economic development; he also plans and edits some special reports

 

Stay informed. Subscribe to BioMed SA news alerts.